<DOC>
	<DOC>NCT02844933</DOC>
	<brief_summary>The primary objectives of this study are to assess the efficacy of Cannabidiol Oral Solution on hyperphagia-related behavior in subjects with Prader-Willi Syndrome (PWS), and to assess the efficacy of Cannabidiol Oral Solution on body weight in subjects with PWS.</brief_summary>
	<brief_title>Cannabidiol Oral Solution for The Treatment of Subjects With Prader-Willi Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Prader-Willi Syndrome</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Meets protocolspecified criteria for qualification and contraception Willing and able to remain confined in the study unit for the entire duration of each treatment period and comply with restrictions related food, drink and medications Voluntarily consents to participate and provides written informed consent prior to any protocolspecific procedures History or current use of overthecounter medications, dietary supplements, or drugs (including nicotine and alcohol) outside protocolspecified parameters Signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise: 1. the safety or wellbeing of the participant or study staff; 2. the safety or wellbeing of the participant's offspring (such as through pregnancy or breastfeeding); 3. the analysis of results</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>